Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Eton submitted a prior approval supplement seeking expanded indication for KHINDIVI® hydrocortisone oral solution.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Eton submitted a prior approval supplement seeking expanded indication for KHINDIVI® hydrocortisone oral solution
- Regulatory submission creates potential for broader commercial use, subject to FDA approval
- Press release dated July 29, 2026 provides additional submission details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA Prior Approval Supplement submitted to expand KHINDIVI from patients 5+ to younger pediatric patients
- New formulation demonstrated bioequivalence to ALKINDI SPRINKLE, supporting regulatory pathway without new clinical efficacy evidence
- Potential expanded-label approval targeted for first half 2027, creating a future commercial catalyst
- Addressable U.S. pediatric adrenal insufficiency population estimated at approximately 10,000 patients
- Younger children remain an unmet need, but inactive-ingredient safety concerns require monitoring for hyperosmolarity and metabolic acidosis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.